{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:10:15Z","timestamp":1761808215898,"version":"3.41.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T00:00:00Z","timestamp":1534723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008725","name":"Instytut Farmakologii, Polskiej Akademii Nauk","doi-asserted-by":"publisher","award":["financed from the statute"],"award-info":[{"award-number":["financed from the statute"]}],"id":[{"id":"10.13039\/501100008725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurotox Res"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s12640-018-9939-6","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T05:06:36Z","timestamp":1534741596000},"page":"706-716","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Protective Effect of Repeated 1MeTIQ Administration on the Lactacystin-Induced Impairment of Dopamine Release and Decline in TH Level in the Rat Brain"],"prefix":"10.1007","volume":"34","author":[{"given":"Agnieszka","family":"W\u0105sik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irena","family":"Roma\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Zelek-Molik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irena","family":"Nalepa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucyna","family":"Antkiewicz-Michaluk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,20]]},"reference":[{"key":"9939_CR1","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1248\/bpb.28.1355","volume":"28","author":"K Abe","year":"2005","unstructured":"Abe K, Saitoh T, Horiguchi Y, Utsunomiya I, Taguchi K (2005) Synthesis and neurotoxicity of tetrahydroisoquinoline derivatives for studying Parkinson\u2019s disease. Biol Pharm Bull 28:1355\u20131362","journal-title":"Biol Pharm Bull"},{"key":"9939_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.brainres.2006.02.097","volume":"1087","author":"TB Ahn","year":"2006","unstructured":"Ahn TB, Jeon BS (2006) Protective role of heat shock and heat shock protein 70 in lactacystin-induced cell death both in the rat substantia nigra and PC 12 cells. Brain Res 1087:159\u2013167","journal-title":"Brain Res"},{"key":"9939_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neures.2010.03.008","volume":"67","author":"A Alachkar","year":"2010","unstructured":"Alachkar A, Brotchie JM, Jones OT (2010) Binding of dopamine and 3-methoxytyramine as L-DOPA metabolites to human \u03b12-adrenergic and dopaminergic receptors. Neurosci Res 67:245\u2013249","journal-title":"Neurosci Res"},{"key":"9939_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0014-2999(03)01565-6","volume":"466","author":"L Antkiewicz-Michaluk","year":"2003","unstructured":"Antkiewicz-Michaluk L, Karolewicz B, Roma\u0144ska I, Michaluk J, Bojarski AJ, Vetulani J (2003) 1-Methyl-1,2,3,4-tetrahydroisoquinoline protects against rotenone-induced mortality and biochemical changes in rat brain. Eur J Pharmacol 466:263\u2013269","journal-title":"Eur J Pharmacol"},{"key":"9939_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1017\/S1461145703004036","volume":"7","author":"L Antkiewicz-Michaluk","year":"2004","unstructured":"Antkiewicz-Michaluk L, Wardas J, Michaluk J, Roma\u0144ska I, Bojarski A, Vetulani J (2004) Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. Int J Neuropsychopharmacol 7:155\u2013163","journal-title":"Int J Neuropsychopharmacol"},{"key":"9939_CR6","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/j.1471-4159.2006.03756.x","volume":"97","author":"L Antkiewicz-Michaluk","year":"2006","unstructured":"Antkiewicz-Michaluk L, \u0141azarewicz JW, Patsenka A, Kajta M, Ziemi\u0144ska E, Sali\u0144ska E, W\u0105sik A, Go\u0142embiowska K, Vetulani J (2006) The mechanism of 1,2,3,4-tetrahydroisoquinolines neuroprotection: the importance of free radicals scavenging properties and inhibition of glutamate-induced excitotoxicity. J Neurochem 97:846\u2013856","journal-title":"J Neurochem"},{"key":"9939_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejphar.2008.09.033","volume":"599","author":"L Antkiewicz-Michaluk","year":"2008","unstructured":"Antkiewicz-Michaluk L, Ossowska K, Roma\u0144ska I, Michaluk J, Vetulani J (2008) 3-Methoxytyramine, an extraneuronal dopamine metabolite plays a physiological role in the brain as an inhibitory regulator of catecholaminergic activity. Eur J Pharmacol 599:32\u201335","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"9939_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12640-013-9402-7","volume":"25","author":"L Antkiewicz-Michaluk","year":"2014","unstructured":"Antkiewicz-Michaluk L, W\u0105sik A, Michaluk J (2014) 1-Methyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine with unexpected mechanism of action: new vistas of therapeutic application. Neurotox Res 25(1):1\u201312","journal-title":"Neurotox Res"},{"key":"9939_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fnbeh.2015.00068","volume":"9","author":"E Bentea","year":"2015","unstructured":"Bentea E, Van der Perren A, Van Lieffenringe J, El Arfani A, Albertini G, Demuyser T, Merck E, Michotte Y, Smolders I, Baekelandt V, Massie A (2015) Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated \u03b1-synuclein. Front Behav Neurosci 9:68","journal-title":"Front Behav Neurosci"},{"key":"9939_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3233\/JPD-160921","volume":"7","author":"E Bentea","year":"2017","unstructured":"Bentea E, Verbruggen L, Massie A (2017) The proteasome inhibition model of Parkinson\u2019s disease. J Park Dis 7:31\u201363","journal-title":"J Park Dis"},{"key":"9939_CR11","doi-asserted-by":"publisher","first-page":"7151","DOI":"10.1093\/emboj\/17.24.7151","volume":"17","author":"A Ciechanover","year":"1998","unstructured":"Ciechanover A (1998) The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 17:7151\u20137160","journal-title":"EMBO J"},{"issue":"15","key":"9939_CR12","doi-asserted-by":"publisher","first-page":"8545","DOI":"10.1074\/jbc.273.15.8545","volume":"273","author":"G Fenteany","year":"1998","unstructured":"Fenteany G, Schreiber SL (1998) Lactacystin, proteasome function, and cell fate. J Biol Chem 273(15):8545\u20138548","journal-title":"J Biol Chem"},{"key":"9939_CR13","doi-asserted-by":"publisher","first-page":"8955","DOI":"10.1523\/JNEUROSCI.23-26-08955.2003","volume":"23","author":"F Fornai","year":"2003","unstructured":"Fornai F, Lenzi P, Gesi M, Ferrucci M, Lazzeri G, Busceti CL, Ruffoli R, Soldani P, Ruggieri S, Alessandr\u00ec MG, Paparelli A (2003) Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J Neurosci 23:8955\u20138966","journal-title":"J Neurosci"},{"key":"9939_CR14","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.2165\/00003495-200059060-00004","volume":"59","author":"S Kaakkola","year":"2000","unstructured":"Kaakkola S (2000) Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson\u2019s disease. Drugs 59:1233\u20131250","journal-title":"Drugs"},{"key":"9939_CR15","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1046\/j.1471-4159.1994.63030972.x","volume":"63","author":"F Karoum","year":"1994","unstructured":"Karoum F, Chrapusta SJ, Egan MF (1994) 3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. J Neurochem 63:972\u2013979","journal-title":"J Neurochem"},{"issue":"1","key":"9939_CR16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0090-9556(25)07094-1","volume":"19","author":"K Kikuchi","year":"1991","unstructured":"Kikuchi K, Nagatsu Y, Makino Y, Mashino T, Ohta S, Hirobe M (1991) Metabolism and penetration through blood-brain barrier of parkinsonism-related compounds. 1,2,3,4-Tetrahydroisoquinoline and 1-methyl-1,2,3,4-tetrahydroisoquinoline. Drug Met Dis 19(1):257\u2013262","journal-title":"Drug Met Dis"},{"key":"9939_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bbr.2013.12.019","volume":"261","author":"J Konieczny","year":"2014","unstructured":"Konieczny J, Czarnecka A, Lenda T, Kami\u0144ska K, Lorenc-Koci E (2014) Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the substantia nigra. Behav Brain Res 261:79\u201388","journal-title":"Behav Brain Res"},{"key":"9939_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.brainres.2004.12.036","volume":"1036","author":"CS Lee","year":"2005","unstructured":"Lee CS, Han ES, Park ES, Bang H (2005) Inhibition of MG 132-induced mitochondrial dysfunction and cell death in PC 12 cells by 3-morpholinosydnonimine. Brain Res 1036:18\u201326","journal-title":"Brain Res"},{"key":"9939_CR19","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1097\/NEN.0b013e318186de64","volume":"67","author":"X Li","year":"2008","unstructured":"Li X, Du Y, Fan X, Yang D, Luo G, Le W (2008) c-Jun N-terminal kinase mediates lactacystin-induced dopamine neuron degeneration. J Neuropathol Exp Neurol 67:933\u2013944","journal-title":"J Neuropathol Exp Neurol"},{"key":"9939_CR20","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.neuint.2011.03.013","volume":"58","author":"E Lorenc-Koci","year":"2011","unstructured":"Lorenc-Koci E, Lenda T, Antkiewicz-Michaluk L, Wardas J, Domin H, \u015amia\u0142owska M, Konieczny J (2011) Different effects of intranigral and intrastriatal administration of the proteasome inhibition lactacystin on typical neurochemical and histological markers of Parkinson\u2019s disease in rats. Neurochem Int 58:839\u2013849","journal-title":"Neurochem Int"},{"key":"9939_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.expneurol.2013.03.021","volume":"247","author":"S Mackey","year":"2013","unstructured":"Mackey S, Jing Y, Flores J, Dinelle K, Doudet DJ (2013) Direct intranigral administration of an ubiquitin proteasome system inhibitor in rat; behavior, positron emission tomography, immunohistochemistry. Exp Neurol 247:19\u201324","journal-title":"Exp Neurol"},{"key":"9939_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.expneurol.2012.08.008","volume":"238","author":"D Martins-Bianco","year":"2012","unstructured":"Martins-Bianco D, Esteves AR, Santos D, Arduino DM, Swerdlow RH, Oliveira CR, Januario C, Cardoso SM (2012) Ubiquitin proteasome system in Parkinson\u2019s disease: a keeper or a witness? Exp Neurol 238:89\u201399","journal-title":"Exp Neurol"},{"key":"9939_CR23","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1097\/00001756-200208070-00018","volume":"13","author":"KS McNaught","year":"2002","unstructured":"McNaught KS, Bjorklund LM, Belizaire R, Isacson O, Jenner P, Olanow CW (2002) Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 13:1437\u20131441","journal-title":"Neuroreport"},{"key":"9939_CR24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0304-3940(00)01701-8","volume":"297","author":"KS McNaught","year":"2001","unstructured":"McNaught KS, Jenner P (2001) Proteasomal function is impaired in substantia nigra in Parkinson\u2019s disease. Neurosci Lett 297:191\u2013194","journal-title":"Neurosci Lett"},{"key":"9939_CR25","doi-asserted-by":"publisher","first-page":"39550","DOI":"10.1074\/jbc.M603950200","volume":"281","author":"VD Nair","year":"2006","unstructured":"Nair VD, McNaught KS, Gonzalez-Maeso J, Sealfon SC, Olanow CW (2006) p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J Biol Chem 281:39550\u201339560","journal-title":"J Biol Chem"},{"key":"9939_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000202972","volume":"87","author":"C Niu","year":"2009","unstructured":"Niu C, Mei J, Pan Q, Fu X (2009) Nigral degeneration with inclusion body formation and behavioral changes in rats after proteasomal inhibition. Stereotact Funct Neurosurg 87:69\u201381","journal-title":"Stereotact Funct Neurosurg"},{"issue":"1","key":"9939_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1046\/j.1471-4159.2000.0750065.x","volume":"75","author":"J Parrado","year":"2000","unstructured":"Parrado J, Absi E, Ayala A, Casta\u00f1o A, Cano J, Machado A (2000) The endogenous amine 1-methyl-1,2,3,4- tetrahydroisoquinoline prevents the inhibition of complex I of the respiratory chain produced by MPP(+). J Neurochem 75(1):65\u201371","journal-title":"J Neurochem"},{"key":"9939_CR28","first-page":"727","volume":"56","author":"A Patsenka","year":"2004","unstructured":"Patsenka A, Antkiewicz-Michaluk L (2004) Inhibition of rodent brain monoamine oxidase and tyrosine hydroxylase by endogenous compounds-1,2,3,4-tetrahydroisoquinoline alkaloids. Pol J Pharmacol 56:727\u2013734","journal-title":"Pol J Pharmacol"},{"key":"9939_CR29","unstructured":"Patsenka A, Michaluk J, Antkiewicz-Michaluk L (2004) Tetrahydroisoquinoline alkaloids as endogenous inhibitors of brain monoamine oxidase, tyrosine hydroxylase and uptake of monoamines: in vitro study. In 13th International Symposium on Molecular and Physiological Aspects of Regulatory Processes of the Organism. Krakow, Poland, Abstracts, p. 344"},{"key":"9939_CR30","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00429-013-0669-5","volume":"220","author":"IS Pienaar","year":"2015","unstructured":"Pienaar IS, Harrison IF, Elson JL, Bury A, Woll P, Simon AK, Dexter DT (2015) An animal model mimicking pedunculopontine nucleus cholinergic degeneration in Parkinson\u2019s disease. Brain Struct Funct 220:479\u2013500","journal-title":"Brain Struct Funct"},{"key":"9939_CR31","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/0006-291X(86)90972-1","volume":"135","author":"RR Ramsay","year":"1986","unstructured":"Ramsay RR, Salach JI, Dadgar J, Singer TP (1986) Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. Biochem Biophys Res Commun 135:269\u2013275","journal-title":"Biochem Biophys Res Commun"},{"key":"9939_CR32","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/jnc.12686","volume":"129","author":"J Segura-Aguilar","year":"2014","unstructured":"Segura-Aguilar J, Paris I, Mu\u00f1oz P, Ferrari E, Zecca L, Zucca FA (2014) Protective and toxic roles of dopamine in Parkinson\u2019s disease. J Neurochem 129:898\u2013915","journal-title":"J Neurochem"},{"key":"9939_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0896-6273(01)00177-5","volume":"29","author":"MY Sherman","year":"2001","unstructured":"Sherman MY, Goldberg AL (2001) Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29:15\u201332","journal-title":"Neuron"},{"key":"9939_CR34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1146\/annurev-pathol-011110-130242","volume":"6","author":"JM Shulman","year":"2011","unstructured":"Shulman JM, De Jager PL, Feany MB (2011) Parkinson\u2019s disease: genetics and pathogenesis. Annu Rev Pathol 6:193\u2013222","journal-title":"Annu Rev Pathol"},{"issue":"8","key":"9939_CR35","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1096\/fasebj.9.8.7768351","volume":"9","author":"TP Singer","year":"1995","unstructured":"Singer TP, Ramsay RR (1995) Flauoprotein structure and mechanism 2. Monoamine oxidases: old friends hold many surprises. FASEB J 9(8):605\u2013610","journal-title":"FASEB J"},{"key":"9939_CR36","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","volume":"95","author":"MG Spillatini","year":"1998","unstructured":"Spillatini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 95:6469\u20136473","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9939_CR37","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00213-013-3118-5","volume":"229","author":"WL Sun","year":"2013","unstructured":"Sun WL, Zelek-Molik A, McGinty JF (2013) Short and long access to cocaine self-administration activates tyrosine phosphatase STEP and attenuates GluN expression but differentially regulates GluA expression in the prefrontal cortex. Psychopharmacology 229:603\u2013613","journal-title":"Psychopharmacology"},{"key":"9939_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2202-11-1","volume":"11","author":"AC Vernon","year":"2010","unstructured":"Vernon AC, Johansson SM, Modo MM (2010) Noninvasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson\u2019s disease. BMC Neurosci 11:1","journal-title":"BMC Neurosci"},{"key":"9939_CR39","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s12640-015-9556-6","volume":"29","author":"A W\u0105sik","year":"2016","unstructured":"W\u0105sik A, Roma\u0144ska I, Michaluk J, Zelek-Molik A, Nalepa I, Antkiewicz-Michaluk L (2016a) Neuroprotective effect of endogenous amine 1MeTIQ in animals model of Parkinson\u2019s disease. Neurotox Res 29:351\u2013363","journal-title":"Neurotox Res"},{"issue":"6","key":"9939_CR40","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.pharep.2016.08.004","volume":"68","author":"A W\u0105sik","year":"2016","unstructured":"W\u0105sik A, Polak D, Roma\u0144ska I, Michaluk J, Antkiewicz-Michaluk L (2016b) The impact of 1MeTIQ on the dopaminergic system function in the 6-OHDA model of Parkinson\u2019s disease. Pharmacol Rep 68(6):1205\u20131213","journal-title":"Pharmacol Rep"},{"key":"9939_CR41","doi-asserted-by":"crossref","unstructured":"W\u0105sik A, Roma\u0144ska I, Zelek-Molik A, Antkiewicz-Michaluk L (2018) Multiple administration of endogenous amines TIQ and 1MeTIQ protects against a 6-OHDA-induced essential fall of dopamine release in the rat striatum: in vivo microdialysis study. Neurotox Res 33(3):523\u2013531","DOI":"10.1007\/s12640-017-9824-8"},{"key":"9939_CR42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/B978-0-12-386467-3.00007-8","volume":"100","author":"O Weinreb","year":"2011","unstructured":"Weinreb O, Amit T, Riederer P, Youdim MB, Mandel SA (2011) Neuroprotective profile of the multitargeted drug rasagiline in Parkinson\u2019s disease. Int Rev Neurobiol 100:127\u2013149","journal-title":"Int Rev Neurobiol"},{"key":"9939_CR43","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0006-8993(93)91664-E","volume":"612","author":"KN Westlund","year":"1993","unstructured":"Westlund KN, Krakower TJ, Kwan SW, Abell CW (1993) Intracellular distribution of monoamine oxidase A in selected regions of rat and monkey brain and spinal cord. Brain Res 612:221\u2013230","journal-title":"Brain Res"},{"key":"9939_CR44","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S0304-3940(99)00786-7","volume":"276","author":"T Yamakawa","year":"1999","unstructured":"Yamakawa T, Kotake Y, Fujitani M, Shintani H, Makino Y, Ohta S (1999) Regional distribution of parkinsonism-preventing endogenous tetrahydroisoquinoline derivatives and an endogenous parkinsonism-preventing substance-synthesizing enzyme in monkey brain. Neurosci Lett 276:68\u201370","journal-title":"Neurosci Lett"},{"key":"9939_CR45","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1006\/bbrc.1997.6946","volume":"236","author":"T Yamakawa","year":"1997","unstructured":"Yamakawa T, Ohta S (1997) Isolation of 1-methyl-1,2,3,4-tetrahydroisoquinoline-synthesizing enzyme from rat brain: a possible Parkinson\u2019s disease-preventing enzyme. Biochem Biophys Res Commun 236:676\u2013681","journal-title":"Biochem Biophys Res Commun"},{"key":"9939_CR46","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0304-3940(98)00913-6","volume":"259","author":"T Yamakawa","year":"1999","unstructured":"Yamakawa T, Ohta S (1999) Biosynthesis of a parkinsonism-preventing substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline, is inhibited by parkinsonism-inducing compounds in rat brain mitochondrial fraction. Neurosci Lett 259:157\u2013160","journal-title":"Neurosci Lett"}],"container-title":["Neurotoxicity Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12640-018-9939-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-018-9939-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-018-9939-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T12:08:28Z","timestamp":1751803708000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12640-018-9939-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,20]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["9939"],"URL":"https:\/\/doi.org\/10.1007\/s12640-018-9939-6","relation":{},"ISSN":["1029-8428","1476-3524"],"issn-type":[{"type":"print","value":"1029-8428"},{"type":"electronic","value":"1476-3524"}],"subject":[],"published":{"date-parts":[[2018,8,20]]},"assertion":[{"value":"11 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}